|
Cardiovascular events
|
3008 (2)
|
0.75 [0.56, 0.99]
|
0%
|
56
|
74
|
− 19 [− 1, − 33]
|
High
|
|
Percent change of LDL-C
|
3957 (9)
|
− 22.91 [− 27.35, − 18.47]
|
99%
|
–
|
–
|
–
|
Moderate#
|
|
New-onset or worsening diabetes
|
3621 (4)
|
0.65 [0.44, 0.96]
|
23%
|
38
|
58
|
− 20 [− 2, − 32]
|
Moderate§
|
|
Percent change of CRP
|
3555 (7)
|
− 24.70 [− 32.10, − 17.30]
|
53%
|
–
|
–
|
–
|
Moderate#
|
|
Myocardial infarction
|
3008 (2)
|
0.54 [0.25, 1.15]
|
37%
|
12
|
22
|
− 10 [− 17, 3]
|
Moderate§,#
|
|
Coronary revascularization
|
3008 (2)
|
0.74 [0.50, 1.10]
|
0%
|
29
|
39
|
− 10 [− 20, 4]
|
Moderate§
|
|
Cardiovascular death
|
3008 (2)
|
1.65 [0.46, 5.98]
|
0%
|
5
|
3
|
2 [− 2, 15]
|
Moderate§
|
|
Nonfatal stroke
|
3008 (2)
|
1.11 [0.34, 3.61]
|
0%
|
4
|
4
|
0 [− 3, 10]
|
Moderate§
|
|
Hospitalization for unstable angina
|
2574 (2)
|
0.84 [0.41, 1.73]
|
51%
|
11
|
13
|
− 2[− 8, 9]
|
Low#,§
|
|
Any adverse event
|
4188 (9)
|
1.01 [0.97, 1.05]
|
40%
|
712
|
705
|
7 [− 21, 35]
|
Low&,#
|
|
Serious adverse event
|
4184 (9)
|
1.06 [0.89, 1.26]
|
0%
|
126
|
119
|
7 [− 13, 31]
|
Moderate&
|
|
Muscular-related adverse event
|
2703 (3)
|
1.12 [0.80, 1.56]
|
26%
|
120
|
107
|
13 [− 21, 60]
|
Moderate§
|
|
Decrease in glomerular filtration rate
|
3276 (3)
|
3.61 [0.81, 16.04]
|
0%
|
4
|
1
|
3 [− 1, 14]
|
Low*
|
|
Increase in blood creatinine
|
3482 (4)
|
2.15[0.81, 5.69]
|
0%
|
6
|
3
|
3 [− 1, 16]
|
Moderate§
|
|
Increase in blood uric acid
|
1176 (3)
|
3.76 [1.24, 11.39]
|
0%
|
30
|
8
|
22 [2,81]
|
Low*
|
|
Gout
|
3421 (4)
|
2.37 [0.88, 6.36]
|
12%
|
12
|
5
|
7 [− 1, 43]
|
Moderate§
|
|
Neurocognitive disorders
|
3076 (3)
|
0.94 [0.41, 2.17]
|
0%
|
8
|
8
|
0 [− 5, 9]
|
Moderate§
|
|
ALT or AST > 3 × ULN
|
3382 (5)
|
1.97 [0.61, 6.34]
|
0%
|
6
|
3
|
3 [− 1, 14]
|
Moderate§
|
|
CK > 5 × ULN
|
3382 (5)
|
1.31 [0.23, 7.50]
|
19%
|
3
|
2
|
1 [− 1, 12]
|
Moderate§
|
